CTOs on the Move

Mapp Biopharmaceutical

www.mappbio.com

 
Mapp Biopharmaceutical Inc is a Biotechnology company located in 6160 Lusk Blvd Ste C105, San Diego, California, United States.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.mappbio.com
  • 6160 Lusk Blvd. # C105
    San Diego, CA USA 92121
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Mapp Biopharmaceutical raised $16.5M on 06/23/2019

Similar Companies

Id Labs Inc

Id Labs Inc is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aileron Therapeutics

Aileron Therapeutics, based in Cambridge, Massachusetts, is a biopharmaceutical company developing and advancing a revolutionary class of drugs called Stapled Peptides. The company`s proprietary Stapled Peptides platform is a breakthrough approach to creating drugs for highly sought after biological targets using its novel peptide stabilizing technologies.

Somatic Therapies

Somatic Therapies is a Grand Junction, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AlloVir

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Connect Biopharma

Connect Biopharma (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.